Our data thus strongly suggest SIRT7 represents a druggable target in human cancer and provides valuable preclinical evidences supporting compounds 2800Z and 40569Z as starting leads for the development of new therapeutic options against liver cancer. Here, SIRT7 is linked to cancer.